External Controls: Sarepta’s DMD Gene Therapy Not In the Same Boat As Zolgensma, US FDA Says

17 May 2023

Sarepta conducted study-level and integrated-level comparison analyses of SRP-9001-treated patients and external controls. However, heterogeneous nature of DMD and potentially moderate treatment effect of SRP-9001 distinguish it from Novaritis' spinal muscular atrophy treatment, where natural history data were used to support single-arm trial results, the FDA said.

Looking out window — Sarepta looked outside the SRP-9001 clinical program to contextualize the gene therapy's clinical efficacy results. • Source: Shutterstock

External Controls: Sarepta’s DMD Gene Therapy Not In the Same Boat As Zolgensma, US FDA Says

More from US FDA Performance Tracker

More from Regulatory Trackers